Nasal vaccines Market Overview
Nasal vaccines are the administration of mucosal vaccines through nasal route using a nasal sprayer or intra-nasal drop. Mucosal infections are caused by several groups of bacteria and viruses. Mucosal immunization is advantageous than the conventional administration routes due to the induction of both systemic and mucosal immune responses, additional pathogen protection by mucosal secretory IgA antibodies at entry site and its non-invasive nature.
According to the Forum of International Respiratory Societies, lower respiratory tract infection and pneumonia claim 4 million lives every year. World Health Organization (WHO) stated, over 3 to 5 million hospitalized and 0.2 million deaths reported due to influenza.
Nasal vaccines, due to their non-invasiveness, easy access and better immunization are emerging as viable administration alternate to oral or intramuscular administrations. Nasal vaccines may confer protection to the mucosa of lungs, genital tract and intestines.
The global nasal vaccines market is lucrative and is anticipated to register to boost growth with the progressing R&D, Coronavirus emergence, past paced clinical trials and increasing prevalence of other respiratory infections.
Surging cases of respiratory infections such as Streptococcus, Enterobacteriaceae, and viral such as Haemophilus influenza, Coronavirus, Adenovirus and others are propelling the nasal vaccines market growth. Also, the advantageous properties of nasal vaccines, increased compliance, key players and R&D progress are promoting the market growth.
Nasal vaccines emerges as a viable vaccine delivery alternate due to its non-invasiveness, better absorption in microvilli surface, protection from infection at entry site and elicits both mucosal systemic immune response. Drug manufacturers are working with the novel strategy of nasal vaccines development including live-attenuated-pathogen, adjuvants, nanoparticles, mucoadhesives, viruses-like-particles, DNA-vaccines and lipid-based-particulates.
However several challenges constraints the nasal vaccines market growth such as restricted delivery volume (up-to 25 to 200 microlitre), limited efficacy and altered drug permeability due to mucociliary activities, poor antigen retention, limited compatible adjuvants, adverse reactions including mild fever and ache.
Nasal vaccines application does not apply to infants and allergic patients. Nasal vaccines delivery strategies require more research for better administration and to broaden disease coverage. The additional cost of nasal vaccines delivery devices and regulatory obligations hamper the nasal vaccines market growth, with the major challenge of implementing in vivo data into clinical results.
Although the overall global nasal vaccines market is poised to grow with the increasing compliance of nasal vaccines, improving design strategies, healthcare delivery settings, looming prevalence of respiratory disease and pandemic threat pushing the market for massive vaccination objectives.
Several efficient and safer co-adjuvants have been developed such as ChiSys® for norovirus. Also, emerging nasal vaccines such as FluMist Quadrivalent, NanoStat, Nasovac™ and many others, are fuelling the market.
The global nasal vaccines market is anticipated to grow with the looming viral pandemic and respiratory infections and high acceptance of nasal vaccines. By type, COVID-19 vaccines dominate the segment of nasal vaccines types due to its massive R&D, fast-paced clinical trials to curb the global infections and deaths.
By applications, children lead the nasal vaccines application segment due to the high efficacy. Immunose™ FLU approved for influenza for children and FluMist nasal spray is more effective in children than adults. By dosage form, nasal spray vaccine dominates the nasal vaccines market with the giant market of influenza, Alzheimer’s disease, swine flu and adenovirus, also the rigorous R&D for COVID-19 vaccine development have a deliberated focus on nasal spray vaccines.
Europe holds the largest global nasal vaccines market due to their advanced nasal vaccine delivery systems, high compliance, surging tolls of COVID-19 and other respiratory infections and government support. Europe has experienced diverse COVID-19 outbreaks, along with the increased investment into nasal vaccines R&D for COVID-19.
Asia-pacific region holds the significant global nasal vaccines market with the fastest growth attributed by the rigorous R&D, regional market players, the active collaboration of government and drug manufacturers to develop a vaccine for threatening viral pandemic, COVID-19 and others respiratory infections.
Nasal spray vaccines are under the prime focus for COVID-19 vaccine in China and India. North America nasal vaccine market is growing with active contribution from Canada having vast acceptance, advanced R&D and healthcare infrastructure of nasal vaccines.
Latin America nasal vaccines market is supported by the elevating research and clinical developments of nasal vaccines for influenza and COVID-19. MEA & Africa region has a stagnant nasal vaccines market due to the poor healthcare and research facilities, however nasal vaccine market growth is expected to elevate by the advancing research and healthcare of Israel and South-Africa.
The key players of nasal vaccines market include
- Serum Institute of India
- Bharat Biotech
- Antares Pharma
- INJEX Pharma GmbH
- PharmaJet and Crossject
The report covers exhaustive analysis on
- Market Segments
- Market Dynamics
- Historical Actual Market Size, 2015 - 2019
- Market Size & Forecast 2020 to 2030
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Market Drivers and Restraints
Regional analysis includes
- North America
- Latin America
- South Asia
- East Asia
- Middle East & Africa
The global nasal vaccines market is segmented into types, applications, dosage form and regions.
- Flu Vaccines
- COVID-19 Vaccines
- Other Vaccines
Dosage Form :